Effects of Melatonin Supplementation on Serum Oxidative Stress Markers and Disease Activity in Systemic Lupus Erythematosus Patients: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Disease Activity ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Oxidative Stress Markers ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Stress Markers

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.34502 ◽

2012 ◽

Vol 64 (9) ◽

pp. 2937-2946 ◽

Cited By ~ 194

Author(s):

Zhi-Wei Lai ◽

Robert Hanczko ◽

Eduardo Bonilla ◽

Tiffany N. Caza ◽

Brandon Clair ◽

...

Keyword(s):

T Cells ◽

Disease Activity ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Systemic Lupus ◽

Double Blind ◽

THU0030 Nutritional Status in Relation to Inflammatory and Oxidative Stress Markers: Association with Disease Activity in Patients with Systemic Lupus Erythematosus

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.2769 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 186.3-187

Author(s):

S. Abou-Raya ◽

A. Abou-Raya ◽

M. Helmii

Keyword(s):

Oxidative Stress ◽

Nutritional Status ◽

Disease Activity ◽

Lupus Erythematosus ◽

Oxidative Stress Markers ◽

Systemic Lupus ◽

Stress Markers ◽

And Oxidative Stress

Faculty Opinions recommendation of N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717970360.793468961 ◽

2013 ◽

Author(s):

Mark Boothby

Keyword(s):

T Cells ◽

Disease Activity ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Systemic Lupus ◽

Double Blind ◽

Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

Rheumatology International ◽

10.1007/s00296-013-2811-3 ◽

2013 ◽

Vol 33 (11) ◽

pp. 2789-2796 ◽

Cited By ~ 28

Author(s):

Kayode J. Bello ◽

Hong Fang ◽

Parastoo Fazeli ◽

Waleed Bolad ◽

Mary Corretti ◽

...

Keyword(s):

Clinical Trial ◽

Endothelial Dysfunction ◽

Disease Activity ◽

Randomized Clinical Trial ◽

Lupus Erythematosus ◽

Omega 3 ◽

Systemic Lupus ◽

Double Blind ◽

A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.

Annals of the Rheumatic Diseases ◽

10.1136/ard.47.6.496 ◽

1988 ◽

Vol 47 (6) ◽

pp. 496-502 ◽

Cited By ~ 25

Author(s):

C G Mackworth-Young ◽

J David ◽

S H Morgan ◽

G R Hughes

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Intravenous Methylprednisolone ◽

Double Blind ◽

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

Rheumatology and Therapy ◽

10.1007/s40744-021-00351-7 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Dale Wright ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-213032 ◽

2018 ◽

Vol 77 (6) ◽

pp. 883-889 ◽

Cited By ~ 33

Author(s):

Joan T Merrill ◽

William R Shanahan ◽

Morton Scheinberg ◽

Kenneth C Kalunian ◽

David Wofsy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Selective Inhibitor ◽

Phase Iii ◽

Systemic Lupus ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

B Cell Activating Factor

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Rheumatology and Therapy ◽

10.1007/s40744-021-00353-5 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

Richard A. Furie

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial

Arthritis Care & Research ◽

10.1002/acr.22621 ◽

2015 ◽

Vol 68 (1) ◽

pp. 91-98 ◽

Cited By ~ 66

Author(s):

Glauce L. Lima ◽

Juliane Paupitz ◽

Nadia E. Aikawa ◽

Liliam Takayama ◽

Eloisa Bonfa ◽

...

Keyword(s):

Vitamin D ◽

Young Adults ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Systemic Lupus ◽

Juvenile Systemic Lupus Erythematosus ◽

Double Blind ◽

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10681 ◽

2002 ◽

Vol 46 (12) ◽

pp. 3251-3258 ◽

Cited By ~ 257

Author(s):

Kenneth C. Kalunian ◽

John C. Davis ◽

Joan T. Merrill ◽

Mark C. Totoritis ◽

David Wofsy ◽

...

Keyword(s):

T Cell ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Double Blind ◽